JELIDO

ANAESTHETIC LIDOCAINE LUBRICANT

Patient comfort comes first with JELIDO®

  • FACILITATES LUBRICATION

    to make the process of catheter and instrument insertion smoother1

  • HELPS PREVENT PAIN

    with lidocaine, a local anaesthetic1

Easy to use1

Pre-assembled, prefilled, sterile2

One-handed syringe facilitates gel instillation2

JELIDO® lubricating gel: For catheterization and other endourethral operations1

Facilitates catheter and instrument insertion

2% lidocaine hydrochloride helps prevent pain

Rapid, lasting anaesthetic1

After JELIDO® application, the anaesthesia effect:1

Starts to work within 5–15 minutes†

Lasts
~20–30 minutes

Works quickly and delivers a sustained effect consistent with procedural needs.

JELIDO® facilitates lubrication1,2

JELIDO® instillation helps form a lubricating film throughout the urethra and may help open physiological constrictions prior to catheter or instrument insertion1,2

Even distribution of lubricant helps coat the urethral mucosa and facilitates catheter or instrument insertion1,2

Discover how the FARCO®* prefilled syringe design performsExplore features

Lidocaine gel helps reduce pain – Explore the clinical evidence3,4

Cystoscopy

  • Pain experienced during cystoscopy may negatively influence adherence to subsequent surveillance procedures3
  • Clinical evidence indicates that intraurethral lidocaine gel can reduce moderate-to-severe pain during flexible cystoscopy in men compared with lubricating gel alone3,4
Clear lubricating gel

Patients receiving lidocaine gel were‡,3

1.7 x LESS LIKELY TO REPORT MODERATE-TO-SEVERE PAIN

Catheterization

  • Urethral catheterization has been reported to rank among the most painful invasive procedures5
  • Clinical evidence indicates that lidocaine gel can significantly reduce procedural pain compared with lubricating gel alone5
Impact of lidocaine gel on pain during urethral catheterization§,5 Bar graph showing that 2% lidocaine present in lubricating gel can significantly lower pain
  • Lowest pain score (mm)
  • Highest pain score (mm)

Pain intensity (mm)

80

70

60

50

40

30

20

10

0

8.7
38
19.3
58

Lidocaine + lubricant

Lubricant alone

Clinical evidence suggests that lidocaine gel may reduce procedural pain compared with lubricating gel alone5

Adapted from Aygin D, et al., 2017.
Visual Analogue Scale (0–10 cm or 0–100 mm) and the 0- to 10-point rating scale were used to assess the pain the patients experienced during urethral catheterization.

How to use JELIDO®?
INSTILLAGEL

For an antiseptic lubricant gel option for catheterization

Learn more

JELIDO® (lidocaine hydrochloride jelly) is indicated for:1

  • Surface anaesthesia and lubrication for:
    • The male and female urethra during cystoscopy, catheterization, exploration by sound, and other endourethral operations
    • Nasal and pharyngeal cavities in endoscopic procedures such as gastroscopy and bronchoscopy
    • Proctoscopy and rectoscopy
    • Tracheal intubation
  • Symptomatic treatment of pain in connection with cystitis and urethritis

for additional safety information and for a link to the Product Monograph, which discusses:1

  • Contraindications in patients with a hypersensitivity to this drug or any ingredient in the formulation; a known history of hypersensitivity to amide-type local anaesthetics or other formulation components; congenital or idiopathic methemoglobinemia; a need for treatment with methemoglobin-inducing agents (e.g., sulfonamides) in infants ≤ 12 months of age; or glucose-6-phosphate dehydrogenase deficiency
  • Most serious warnings and precautions regarding adherence to the recommended dosage and use in children and infants (< 3 months of age)
  • Other relevant warnings and precautions regarding use of the lowest effective dose; avoiding contact with eyes; familial malignant hyperthermia; increased plasma concentrations in patients under general anaesthesia; use in unparalyzed patients; endotracheal tube lubrication; risk of aspiration; unintentional biting trauma; impairment of locomotion or alertness; caution when driving and operating machinery; and use in patients with porphyria. Use with caution in patients with sepsis; traumatized mucosa at the application site; epilepsy; severe shock; bradycardia; impaired cardiovascular function; hepatic disease or impaired renal function; or known drug sensitivities. Reduced doses should be given in debilitated patients, acutely ill patients, and patients with sepsis. Care should be taken during early pregnancy
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions

INSTILLAGEL® (lidocaine and chlorhexidine gel) is indicated for surface anaesthesia, lubrication, and antisepsis for:6

  • The male and female urethra during cystoscopy
  • Catheterization
  • Exploration by sound and other endourethral operations

Consult the Prescribing Information for contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Prescribing Information is also available by calling 1-888-550-6060.

†Depending on the area of application.
‡Data were derived from meta-analysis using a random-effects model to evaluate the effect of intraurethral lidocaine gel on pain during flexible cystoscopy.
§Data were derived from a systematic review of published studies evaluating the effectiveness of lubricants, including lidocaine gel, in reducing pain during urethral catheterization.

References: 1. JELIDO® Product Monograph. PENDOPHARM®, Division of Pharmascience Inc. February 19, 2026. 2. Sperling H, Lümmen G, Rübben H. The use of lubricants in urology. Indications and results. Urologe. [A] 2005;44(6):662-666. 3. Aaronson DS, Walsh T, Smith J, et al. Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int. 2009;104:506-510. 4. Borch M, Scosyrev E, Baron B, et al. A randomized trial of 2% lidocaine gel versus plain lubricating gel for minimizing pain in men undergoing flexible cystoscopy. Urol Nurs. 2013;33(4):187-193. 5. Aygin D, Usta E. The effect of lubricants used in indwelling bladder catheterization through urethra onprocedure-related pain: a literature review. Int J Clin Exp Med. 2017;10(2):1995-2005. 6. INSTILLAGEL® Prescribing Information. PENDOPHARM®, Division of Pharmascience Inc. February 19, 2025.

PENDOPHARM

JELIDO and UROSAFETIP are registered trademarks of Finchley Research & Development Inc., used under license. INSTILLAGEL is a registered trademark of FARCO-PHARMA GmbH, used under license. PENDOPHARM and its logo are registered trademarks of Finchley Research & Development Inc., used under license.

*Registered trademarks are the property of their respective owners.

© 2026 PENDOPHARM®. All rights reserved.

Publication date: 29-10-2026

Contact us

For any questions about our products or further information about our company, please do not hesitate to contact us.

JELIDO® and INSTILLAGEL® are available at select specialty pharmacies and by special order at most pharmacy outlets.

6111 Royalmount AvenueMontreal (Quebec)H4P 2T4, CanadaTelephone+1 (514) 340-5045Fax+1 (866) 926-7654 or +1 (514) 733-9684

MED INFO

Toll-free Telephone: +1 (888) 550-6060
Fax: +1 (514) 340-0164
E-mail: medinfo@pharmascience.com

PHARMACOVIGILANCE:

By Telephone: +1 (888) 550-6060
By Fax: +1 (866) 551-1939
By E-mail: adr@pharmascience.com

For Medical and Scientific Information Services, Adverse Event Report, and Customer Service, please visit our website at https://pendopharm.com/contact/.

JELIDO® important safety information

Indications and clinical use:

JELIDO® (lidocaine hydrochloride jelly) is indicated for:

  • Surface anaesthesia and lubrication for:
    • The male and female urethra during cystoscopy, catheterization, exploration by sound, and other endourethral operations
    • Nasal and pharyngeal cavities in endoscopic procedures such as gastroscopy and bronchoscopy
    • Proctoscopy and rectoscopy
    • Tracheal intubation
  • Symptomatic treatment of pain in connection with cystitis and urethritis

Pediatrics (2–18 years of age): Children should be given reduced doses commensurate with their age, weight, and physical condition.

Pediatrics (< 2 years of age): Lidocaine should be used with caution in children younger than two years of age as there are insufficient data to support the safety and efficacy of this product in this patient population at this time.

Geriatrics (> 65 years of age): Elderly patients should be given reduced doses commensurate with their age and physical condition.

Contraindications:

  • Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or any component of the container
  • Patients with a known history of hypersensitivity to local anaesthetics of the amide type or to other components in the formulation
  • Patients with congenital or idiopathic methemoglobinemia
  • Infants ≤ 12 months of age who require treatment with methemoglobin-inducing agents (e.g., sulfonamides)
  • Patients with glucose-6-phosphate dehydrogenase deficiency, which makes them more susceptible to drug-induced methemoglobinemia

Most serious warnings and precautions:

  • PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE: EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS OF LIDOCAINE OR ITS METABOLITES AND SERIOUS, AS WELL AS LIFE-THREATENING, ADVERSE EFFECTS, including methemoglobinemia.
  • Use in children and infants (< 3 months): Ensure the caregiver understands to limit the dose and area of application and to prevent accidental ingestion. Children should be closely observed during and after use of lidocaine as they are at greater risk than adults for serious adverse events (e.g., methemoglobinemia).

Other relevant warnings and precautions:

  • Lowest effective dose should be used
  • Avoid contact with eyes
  • Potential triggering agent for familial malignant hyperthermia
  • In patients under general anaesthesia who are paralyzed, higher plasma concentrations may occur than in spontaneously breathing patients
    • Unparalyzed patients are more likely to swallow a large proportion of the dose, which then undergoes considerable first-pass hepatic metabolism following absorption from the gut
  • Endotracheal tube lubrication
    • Avoid introduction of the jelly into the lumen of the tube
    • Do not use to lubricate the endotracheal stylettes
  • Topical anaesthetics used in the mouth may enhance the danger of aspiration
  • Numbness of the tongue or buccal region may enhance unintentional biting trauma
  • May temporarily impair locomotion or alertness
  • Use with caution in patients with:
    • Sepsis
    • Traumatized mucosa at the area of application
    • Epilepsy
    • Severe shock
    • Bradycardia
    • Impaired cardiovascular function
    • Hepatic disease or impaired renal function
    • Known drug sensitivities
  • Exercise caution when driving and operating machinery
  • Exercise caution with use in all porphyric patients
  • Reduced doses should be given in debilitated patients, acutely ill patients, and patients with sepsis
  • Care should be taken during early pregnancy

For more information:

Consult the Product Monograph for important information relating to adverse events, drug interactions, and dosing that has not been discussed in this piece. The Product Monograph is also available by calling 1-888-550-6060.